<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>55(3)</volume><submitter>Li X</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The current understanding of the prognostic significance of B cells and their role in the tumor microenvironment (TME) in esophageal carcinoma (ESCA) is limited.&lt;h4>Methods&lt;/h4>We conducted a screening for B-cell-related genes through the analysis of single-cell transcriptome data. Subsequently, we developed a B-cell-related gene signature (BRGrisk) using LASSO regression analysis. Patients from The Cancer Genome Atlas cohort were divided into a training cohort and a test cohort. Patients were categorized into high- and low-risk groups based on their median BRGrisk scores. The overall survival was assessed using the Kaplan-Meier method, and a nomogram based on BRGrisk was constructed. Immune infiltration profiles between the risk groups were also compared.&lt;h4>Results&lt;/h4>The BRGrisk prognostic model indicated significantly worse outcomes for patients with high BRGrisk scores (p &lt; 0.001). The BRGrisk-based nomogram exhibited good prognostic performance. Analysis of immune infiltration revealed that patients in the high-BRGrisk group had notably higher levels of immune cell infiltration and were more likely to be in an immunoresponsive state. Enrichment analysis showed a strong correlation between the prognostic gene signature and cancer-related pathways. IC50 results indicated that patients in the low-BRGrisk group were more responsive to common drugs compared to those in the high-BRGrisk group.&lt;h4>Conclusions&lt;/h4>This study presents a novel BRGrisk that can be used to stratify the prognosis of ESCA patients and may offer guidance for personalized treatment strategies aimed at improving prognosis.</pubmed_abstract><journal>Journal of gastrointestinal cancer</journal><pagination>1313-1323</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11347472</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Novel-B-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Esophageal Carcinoma.</pubmed_title><pmcid>PMC11347472</pmcid><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Sun T</pubmed_authors><pubmed_authors>Huang N</pubmed_authors><pubmed_authors>Liu S</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Novel-B-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Esophageal Carcinoma.</name><description>&lt;h4>Background&lt;/h4>The current understanding of the prognostic significance of B cells and their role in the tumor microenvironment (TME) in esophageal carcinoma (ESCA) is limited.&lt;h4>Methods&lt;/h4>We conducted a screening for B-cell-related genes through the analysis of single-cell transcriptome data. Subsequently, we developed a B-cell-related gene signature (BRGrisk) using LASSO regression analysis. Patients from The Cancer Genome Atlas cohort were divided into a training cohort and a test cohort. Patients were categorized into high- and low-risk groups based on their median BRGrisk scores. The overall survival was assessed using the Kaplan-Meier method, and a nomogram based on BRGrisk was constructed. Immune infiltration profiles between the risk groups were also compared.&lt;h4>Results&lt;/h4>The BRGrisk prognostic model indicated significantly worse outcomes for patients with high BRGrisk scores (p &lt; 0.001). The BRGrisk-based nomogram exhibited good prognostic performance. Analysis of immune infiltration revealed that patients in the high-BRGrisk group had notably higher levels of immune cell infiltration and were more likely to be in an immunoresponsive state. Enrichment analysis showed a strong correlation between the prognostic gene signature and cancer-related pathways. IC50 results indicated that patients in the low-BRGrisk group were more responsive to common drugs compared to those in the high-BRGrisk group.&lt;h4>Conclusions&lt;/h4>This study presents a novel BRGrisk that can be used to stratify the prognosis of ESCA patients and may offer guidance for personalized treatment strategies aimed at improving prognosis.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2025-04-19T14:52:28.771Z</modification><creation>2024-11-20T06:17:11.43Z</creation></dates><accession>S-EPMC11347472</accession><cross_references><pubmed>38963643</pubmed><doi>10.1007/s12029-024-01083-x</doi></cross_references></HashMap>